Podcasts about karolinska institutet

OptikerPodden Avsnitt 63 – Marika Wahlberg Ramsay I detta avsnitt gästas OptikerPodden av Marika Wahlberg Ramsay – enhetschef, programdirektor och assisterad lektor vid optikerprogrammet på Karolinska Institutet samt ny styrelseledamot i Optikerförbundet. Vi pratar om Marikas resa in i optikyrket, arbetet med att utbilda framtidens optiker, hur professionen utvecklats och vilka frågor hon brinner för i sitt nya uppdrag inom Optikerförbundet. Ett inspirerande samtal om optometri, utbildning, ledarskap och framtiden för optikbranschen. Stort tack till Optikerförbundet som sponsrar detta avsnitt av OptikerPodden.

In this episode of Success Unlocked, Dr. Adrienne Shnier sits down with Olivia, a former AYG client and team member, to talk about her journey from uncertainty and self-doubt to receiving 10 offers and completing her Master of Medical Science in Health Economics at Karolinska Institutet in Stockholm.When Olivia first reached out to Adrienne, she did not feel like the “ideal candidate.” She questioned her experience, compared herself to others, and wondered why a top European medical university would choose her.Through AYG's Mastering Academic Applications program, Olivia learned how to reframe her story, advocate for herself, and build the strongest version of her own application. She also shares how the mindset, scheduling, and peak performance work she learned at AYG helped her once she was actually in the program.From moving to Sweden to navigating a different education system to rewriting major parts of her thesis two weeks before the deadline, Olivia explains how she learned to stop panicking and start planning through pressure.If you have ever questioned whether you belong in the room, this episode will remind you that you do not need to become someone else to succeed. You need the right strategy, the right support, and the confidence to move forward as yourself.What You'll Learn ✔ How Olivia went from self-doubt to 10 offers ✔ Why there is no single “ideal candidate” ✔ How to reframe your experience for stronger applications ✔ Why scarcity mindset can hold students back ✔ What Olivia learned from studying in Sweden ✔ How AYG's mindset work supported her beyond acceptance ✔ The difference between pushing through pressure and planning through it ✔ Why doing hard things on purpose builds real confidenceMastering Academic Applications: From Scratch to Submission is now open for you to complete your applications in 12-weeks! With live coaching, you develop your applications & gain insights into your applications processes like never before. Join us now using this link to enroll!Connect with Adrienne!Looking for support with your graduate or professional school applications? Connect with us at Apply Yourself Global™! Email me personally at adrienne@applyyourselfglobal.com. You can also DM me on Instagram @applyyourselfglobal.Ask the ExpertHave any questions on applications, success, test prep, and more? Send your questions us, or you can submit an audio file via Instagram DM and we can feature you on the podcast!Work with Adrienne

Inför det kommande valet är hälso- och sjukvården åter en av väljarnas mest prioriterade frågor. En växande befolkning, högt tryck på akutsjukhusen och vårdköer gör prioriteringar inför nästa mandatperiod avgörande både nationellt och i landets regioner. SNS bjuder in ledande forskare, politiker i Region Stockholm och företrädare på nationell nivå till ett fördjupat samtal om partiernas vägval och vilka reformer som är mest avgörande. Vilka samband finns mellan vårdplatsbrist, överbelastade akutmottagningar och patientsäkerhet? Hur bör ansvarsfördelningen mellan stat och regioner utformas och hur påverkar det hur vården organiseras? Välkommen till ett seminarium på SNS där vi diskuterar de viktigaste skiljelinjerna mellan partierna och vad forskningen säger om de vägval som väntar under nästa mandatperiod. Seminariet anordnas som en del i SNS serie Mötesplats vård. Medverkande Talla Alkurdi (S), hälso- och sjukvårdsregionråd , Region Stockholm Anders Anell, professor, Ekonomihögskolan vid Lunds universitet Christian Carlsson (KD), ordförande för socialutskottet Axel Conradi (M), oppositionsregionråd, Region Stockholm Marie Morell (M), vice ordförande i SKR:s sjukvårdsdelegation, ordförande regionstyrelsen, Region Östergötland. Björn af Ugglas, civilingenjör, doktor i medicinsk vetenskap, Karolinska Institutet, grundare DB Evidence AB Samtalet modereras av Anna Norén, forskningsledare på SNS.

IQ engagerar och provocerar, men vad visar forskningen? Med hjälp av Torkel Klingberg, professor i kognitiv neurovetenskap vid Karolinska Institutet, föreläsare och författare, får Jenny Jägerfeld och Jonatan Unge klarhet i hur tillförlitliga intelligenstester är. Hur mycket kan intelligens förändras över livet och har vi verkligen blivit smartare över tid?

Torkel Klingberg är läkare och professor i kognitiv neurovetenskap vid Karolinska Institutet. Hans forskning handlar om hjärnans utveckling och plasticitet, särskilt arbetsminne, uppmärksamhet och lärande hos barn. Han har varit professor sedan 2007 och är även ledamot av Nobelförsamlingen.00:00 Varför ska vi lära oss något i AI-tider?02:20 Hotet mot barns lärande när AI gör jobbet05:19 Därför behöver hjärnan tränas – skola, IQ och kognitiv utveckling08:36 Betyg, läxor och skola när elever kan använda AI10:31 AI som lärare: från fuskverktyg till personlig coach12:19 Arbetsminne, koncentration och varför fokus är en superkraft16:35 Neuro, Cogmed och träning av arbetsminne17:54 Kognitiv friktion: läs svåra böcker och träna hjärnan20:47 Skärmtid är fel fråga – sociala medier vs dataspel23:35 Huberman, TikTok och opium-liknelsen25:30 Blomstringens psykologi: PERMA, mening och utveckling30:01 Blir AI början på mänsklig blomstring – eller fördumning?32:47 AlphaFold, Nobelpris och AI som accelererar vetenskap34:02 AI och jobben: juniora roller, programmerare och framtidens arbetsmarknad37:13 Blir människan domesticerad av AI?38:07 Kognitiv offloading, Flynn-effekten och risken att vi blir dummare40:00 AI-genererat innehåll, filterbubblor och kampen om sanningen45:49 Ska sociala medier förbjudas för barn?49:56 Synergimodellen: growth mindset, stress och motivation54:52 Framtidstro, barnafödande och varför unga inte får ge upp59:26 Utvecklingsoptimism, Abundance och vad AI kan hjälpa oss lösa01:04:10 Vad politiker borde göra åt AI och sociala medier01:05:18 Praktiska takeaways: träna hjärnan och minska distraktioner01:06:00 Vad händer när unga vuxna minskar mobilen?01:08:45 Avslutning med Torkel Klingberg

Läkemedel för viktminskning toppar försäljningslistorna. Och efterfrågan är enorm. Hittills har patienterna fått betala själva men nu ska frågan om vem som ska stå för notan tas upp i domstol. Lyssna på alla avsnitt i Sveriges Radios app. En ”gamechanger” för patienterDen nya typen av viktminskningsmediciner har på kort tid blivit globala försäljningssuccéer. ”De är en gamechanger. Här har vi en möjlighet att komma till viktnedgångar som vi aldrig sett tidigare med medicinsk behandling”, säger Ylva Trolle Lagerros som är professor och överläkare vid Centrum för obesitas i Region Stockholm.En miljard människor med obesitas globaltHär i Sverige beräknas över hälften av den vuxna befolkningen vara överviktig eller ha obesitas, som det kallas när man har ett BMI över 30. Hittills har de som velat ta de nya medicinerna, Wegovy från Novo Nordisk och Mounjaro från Eli Lilly, fått betala ur egen ficka. ”Är du fattig får du vara fet, så enkelt är det”, säger Daniel Brodén som själv betalar runt 5 000 kronor i månaden för sin medicin.Staten vs läkemedelsbolagenMen nu har kampen om vem som ska betala framöver trappats upp till att bli en juridisk strid – med staten på ena sidan och läkemedelsbolaget Novo Nordisk på den andra. ”Obesitas är en allvarlig kronisk sjukdom och den borde få samma förutsättningar som andra kroniska sjukdomar”, säger Mikael Pennanen, chef för samhälls- och myndighetskontakter på Novo Nordisk Sverige. Juridisk stridI februari avslogs deras ansökan om att Wegovy ska subventioneras för patienter med svår obesitas och flera följdsjukdomar. TLV, Tandvårds- och läkemedelsförmånsverket, menar att risken är stor att medicinen skrivs ut till fler än det är tänkt – och att kostnaderna för skattebetalarna riskerar att skena. ”Det är väldigt många som använder de här läkemedlen och det är många som vill ha dem, och vi saknar möjligheter att följa upp att de bara skrivs ut till de mest behövande”, säger enhetschefen Per-Henrik Zingmark. Nu ligger bollen hos Förvaltningsrätten i Stockholm.Programledare och producent:Hanna MalmodinMedverkande och röster i programmet:Ylva Trolle Lagerros, professor vid Karolinska Institutet och överläkare vid Centrum för obesitas i Region StockholmKnut Kainz Rognerud, ekonomikommentator Mikael Pennanen, Head of National Market Access & Pipeline Novo Nordisk Scandinavia ABPer-Henrik Zingmark, enhetschef TLV Daniel BrodénKatarina Steen Carlsson, forskningschef Institutet för hälso- och sjukvårdsekonomi IHEDavid Ricks, vd Eli Lillyekonomiekotextra@sverigesradio.se

From the World Congress of Anesthesiologists in Marrakech, TopMedTalk hosts Mike Grocott and Kate Leslie discuss perioperative cardiac risk assessment with Hilary Grocott, Professor and Head of, The Department of Anesthesiology, Pharmacology & Therapeutics (University of British Columbia) and Michelle Chew Professor of Anesthesiology and Intensive Care Medicine at Karolinska Institutet, Stockholm, Sweden, and editor for the British Journal of Anaesthesia. The conversation reviews perioperative cardiac biomarkers, noting abundant prognostic data but limited evidence for biomarker-led management. The discussion emphasizes that elevated troponins can reflect non-cardiac complications (AKI, PE, sepsis) as well as myocardial injury or heart failure, requiring context-specific follow-up pathways. The group highlights NT-proBNP as a specific marker for heart failure and useful for screening and optimization. The podcast then focuses on pulmonary hypertension and failing right ventricle: detect via history, exam, echo, and biomarkers; prioritize preemptive preparation, arterial beat-to-beat monitoring, modest fluids, early vasopressors/inotropes (norepinephrine, low-dose epinephrine), ventilatory optimization, and vigilant, rapid intervention. If you enjoyed this piece there's a fantastic Perioperative Profile with Michelle Chew you can hear here: https://topmedtalk.libsyn.com/perioperative-profiles-professor-michelle-chew-on-seizing-opportunities-in-anaesthesia-research-editing-and-guideline-work -- Join us at Evidence Based Perioperative Medicine (EBPOM) World Congress 2026 in London. Be part of a global conversation as clinicians from around the world gather between 7-9th July at the British Library in London. Three days of evidence-based perioperative medicine, global insights, and expert debate—featuring speakers including Michael Marmot and Ken Rockwood. Register here - https://ebpom.org/product/ebpom-world-congress-2026/

Hur skapar man möjligheter till ett meningsfullt vardagsliv när resurserna är begränsade – och vad kan arbetsterapi göra för att stärka människors självständighet världen över? I det här samtalet möter vi Susanne Guidetti, professor i arbetsterapi vid Karolinska Institutet. Susanne berättar om sin resa från kliniskt arbete till internationell forskning och delar erfarenheter från projekt både i Sverige och i låg- och medelinkomstländer. Genom konkreta exempel beskriver hon hur arbetsterapi kan göra skillnad i människors vardag – från rehabilitering efter sjukdom eller skada till att skapa nya möjligheter till delaktighet i samhället. Samtalet rör sig mellan forskning, praktik och globala perspektiv på hälsa, och ger en inblick i hur arbetsterapi kan bidra till förändring långt utanför klinikrummet.

Det började som ett sår i ansiktet som aldrig ville läka i dag lever Calle med kronisk cancer. Lyssna på alla avsnitt i Sveriges Radios app. Hudcancer var länge en av de mest dödliga cancerformerna, men med nya behandlingar under 2010-talet förbättrades prognoserna radikalt för de tusentals som drabbas varje år. Samtidigt ökar antalet fall snabbare än någonsin. Den här veckan pratar vi om tecknen du ska vara uppmärksam på, hur mycket vi kan lita på våra solkrämer och hur ny teknik, som AI, kan hjälpa till att upptäcka hudcancer tidigare.Medverkande: Hildur Helgadottir, överläkare inom onkologi Karolinska universitetssjukhuset och cancerforskare vid Karolinska Institutet, Richard Bränström, professor i hälsopsykologi Karolinska Institutet, Sam Polesie, överläkare på hud- och könssjukvård vid Sahlgrenska sjukhuset och docent i dermatologi vid Göteborgs universitet som forskar på AI-modeller vid hudcancerbedömningar, Calle Francke och Hassan Killasli, hudläkare vid Älvsjö hudmottagning.Programledare: Ulrika Hjalmarson NeidemanProducent: Linnéa WanneforsReporter: Caroline Mathiasen

Lågt blodtryck ökar risken för svimningar. Hör Artur Fedorowski, adjungerad professor vid Karolinska Institutet, berätta om riskerna med lågt blodtryck och hur det kan behandlas. I sin forskning kartlägger han förekomsten av POTS, ett tillstånd som bland annat ger hjärtklappning och ökad risk för svimningar och som drabbar patienter med post-covid. Ambitionen på sikt är att hitta botande behandling.

I det här avsnittet träffar jag Ingrid Svensson, ledarskapsforskare och biträdande lektor vid Karolinska Institutet. Samtalet tar sin utgångspunkt i hennes senaste studie, “From I to We”, som undersöker hur chefer i en högpresterande region inom hälso och sjukvården arbetar för att skapa samhörighet, gemensamt ansvar och riktning i organisationen.Vi pratar om vad som händer när ledarskap inte bara ses som något en chef utövar, utan som något som behöver bäras av många tillsammans. Vi kommer också in på varför samhörighet är så central, hur chefer kan skapa förutsättningar för motivation, och varför syftet med verksamheten spelar så stor roll för både prestation och arbetsmiljö.

Om en förälder eller nära släkting får en minnessjukdom är det lätt att undra om det är jag som står näst på tur. Är det jag själv som är sjuk kan det innebära en stor oro för att mina egna barn i framtiden också kommer drabbas. Men hur stor betydelse har egentligen arvet och hur mycket kan jag själv påverka? I detta avsnitt borrar vi oss ner i ärftligheten för den vanligaste minnessjukdomen – Alzheimers sjukdom. Medverkar i samtalet gör Charlotte Magnusson, tidigare byggnadsingenjör som fick en alzheimerdiagnos när hon var 56 år. Nu bygger hon ett sommarhus på Gotland, har skaffat hund och vill leva livet, så länge hon bara kan. Charlotte är orolig för sina vuxna barn. Kommer även de att få sjukdomen? Maria Cavalli, anhörig och grundare av kunskapsportalerna En bra plats, Demenslotsen Alzheimerguiden och Lewyguiden. Marias pappa blev sjuk i alzheimer när hon bara var femton år och hon har flera i sin släkt som är drabbade. Själv har Maria valt att inte ta reda på mer om sitt arv. Varför då? Karin Hållsten, journalist som gjort radiodokumentären ”Du som brukade vara min mamma”, där vi får följa Karin och hennes mamma när hon insjuknar i alzheimer. Karin vill veta allt om sitt arv. Men vad händer om hon, som står mitt i livet, får veta att hon också kommer bli sjuk? Sara García-Ptacek, docent i neurovetenskap och specialistläkare på Karolinska Institutet. I sitt arbete möter hon många patienter med alzheimer och hjälper oss reda ut snårigheterna kring ärftligheten. Samtalsledare är Johanna Hinteregger, själv anhörig. Podden görs i samarbete med Demensförbundet.

Hur mycket styr generna om du blir vänsterhänt? Är vänsterhänta mer kreativa – eller är det en myt? Och löper de större risk att skada sig i en värld anpassad för högerhänta? Jonatan Unge och Jenny Jägerfeld tar hjälp av Patrik Magnusson, forskare i medicinsk genetik och chef för Svenska Tvillingregistret vid Karolinska Institutet. Tillsammans går de igenom forskning, missuppfattningar och oväntade fakta om vänsterhänthet.

As part of the US HUPO sponsored "All the parts", Ben and Ben sat down to talk with Dr. Jan Mulder, Karolinska Institutet.keywords: brain; brain atlas; human protein atlas; Alzheimer's Disease; stereo-seq

Welcome to Ozempic Weightloss Unlocked, where we dive into the latest news on Ozempic from medical breakthroughs to real-life health impacts.Semaglutide, the active ingredient in Ozempic, is showing surprising mental health perks. A large study by researchers from the University of Eastern Finland, Karolinska Institutet, and Griffith University, published in The Lancet Psychiatry, found users had 42 percent fewer psychiatric hospital visits and 44 percent lower depression risk during treatment. Anxiety dropped 38 percent, substance use disorders fell 47 percent, and suicidal behavior risks decreased too. Science Daily reports these benefits may stem from lifestyle changes or direct brain effects.On the innovation front, Eli Lilly's oral pill orforglipron outperformed oral semaglutide in a 52-week phase three trial with 1698 adults with type two diabetes. Science Alert details how orforglipron cut blood sugar more, dropping HbA1c by 1.71 to 1.91 percent versus 1.47 percent, and spurred greater weight loss of 6.1 to 8.2 kilograms compared to 5.3 kilograms. Though more side effects like nausea led to higher dropouts, it's a promising needle-free rival.Stopping Ozempic? A Cleveland Clinic study of nearly eight thousand patients in Diabetes, Obesity and Metabolism challenges rebound fears. Those treated for obesity lost 8.4 percent body weight before stopping and regained just 0.5 percent after one year. Many restarted meds, switched treatments, or adopted lifestyle changes, with 45 percent maintaining or losing more weight.Heart and kidney wins continue: Johns Hopkins Public Health notes GLP-one drugs cut five-year risks of heart attacks and end-stage kidney disease by 15 percent in type one diabetes patients.Exercise matters too. Outside Online highlights a study where aerobic activity preserved muscle during 29-pound average losses on GLP-ones.Long-term, these drugs boost metabolic health, reduce inflammation, and may extend longevity via sustained weight loss, per Health Central and experts like James Hill from the University of Alabama.Real users report two-thirds fewer cravings, per 2026 data from engineering Cambridge.Thanks for tuning in, listeners. Subscribe for more updates. This has been a Quiet Please production, for more check out quietplease.ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Recent studies from the past week highlight new insights into Ozempic and similar GLP-1 medications for weight loss. Researchers from the University of Eastern Finland, Karolinska Institutet in Stockholm, and Griffith University in Australia analyzed large-scale data and found that semaglutide, the active ingredient in Ozempic, significantly reduces risks of depression, anxiety, and addiction alongside its weight loss effects. According to their work published in The Lancet Psychiatry, users experienced a 44 percent lower risk of depression and a 38 percent drop in anxiety disorders during treatment periods. Psychiatric hospital visits fell by 42 percent, and substance use disorders decreased by 47 percent compared to times without the medication. The team suggests these benefits may stem from lifestyle changes or direct effects on the brain.Another study from Washington University School of Medicine, reported by Fox News, warns that stopping GLP-1 drugs like Ozempic quickly erodes heart health gains. Continuous use over three years lowered cardiovascular risk by 18 percent through reductions in cholesterol, blood pressure, inflammation, and insulin resistance. However, quitting for six months raised risk by 4 percent, one year by 14 percent, and two years by 22 percent. Restarting the drugs provided partial protection, only 12 percent, indicating some lasting damage from discontinuation. Lead researcher Ziyad Al-Aly described this as metabolic whiplash, with silent reversals in metabolic health that could lead to heart attacks or strokes.Oprah Winfrey continues to draw attention for her weight loss transformation using GLP-1 medications. The List reports that recent before-and-after photos from events like the 2025 Tony Awards reveal Ozempic neck, a sagging, crepey skin effect under the jaw due to rapid fat loss outpacing skin adjustment. Winfrey has been seen favoring high-necked outfits to camouflage the loose folds, a common side effect among users.These developments underscore the dual-edged nature of Ozempic for weight management, offering mental and heart benefits during use but posing challenges with side effects and discontinuation.Thanks for tuning in, listeners, please subscribe, and remember, this episode was brought to you by Quiet Please podcast networks. For more content like this, please go to Quiet Please dot Ai. Come back next week for more.Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Som 16-åring bor Dessi Hietala i en liten by och mår så dåligt att hon inte vill leva. Sen förändras allt. Lyssna på alla avsnitt i Sveriges Radios app. En kväll i början av 2010-talet sitter Dessi Hietala i sitt flickrum med en hög med piller och en spritflaska framför sig.Det går inte som planerat. Hon överlever. Kort därefter får hon en diagnos: bipolär sjukdom.Idag bor Dessi Hietala i Stockholm och uppträder med etablerade komiker som Magnus Betnér, Kirsty Armstrong och Henrik Nyblom. Samtidigt puttrar hennes depression och ångest på.Hur kan man få andra att skratta kväll efter kväll, när man själv mår riktigt dåligt?Medverkande:Dessi Hietala, komikerMats Lekander, professor i hälsopsykologi vid Karolinska Institutet och vid Stockholms Universitet Magnus Betnér, komikerHenrik Nyblom, komikerEtt program av Anni Riit'aho och Maiju Ristkari maiju.ristkari@sverigesradio.seProducent: Maiju RistkariManus: Anni Riit'aho, Maiju Ristkari och Tiina Laitila KälvemarkBerättare: Ramin FarzinSlutmix: Björn NitzlerArkivklipp: Magnus Betnérs YoutubekanalProgrammet gjordes hösten 2025 och våren 2026.Programmet innehåller berättelser om psykisk ohälsa. Behöver du hjälp eller stöd?Mind Självmordslinjen: 90 101 eller chatta härMind Livslinjen: chatta härHjälplinjen: 90 390Vid livshotande situationer, ring alltid 112.Fler dokumentärer från Sveriges Radio Finska hittar du här.

Wie beeinflusst Epigenetik den Verlauf der Multiplen Sklerose – und welche Rolle spielt dabei die DNA-Methylierung? In diesem spannenden Interview spreche ich mit Dr. Majid Pahlevan Kakhki über neue Erkenntnisse aus der Forschung und mögliche zukünftige Therapieansätze.

För 18-åriga Alma Larsson var basketen allt, när hon plötsligt fick ont i ryggen under ett träningspass. Smärtan visade sig vara ett diskbråck ett vanligt men ofta missförstått ryggproblem. Lyssna på alla avsnitt i Sveriges Radios app. Ryggsmärta är ett av våra vanligaste hälsoproblem och nästan alla vuxna får ont någon gång. Men hur farligt är det egentligen när ryggen gör ont? Den här veckan följer vi Alma Larsson, som fick diskbråck som 18-åring mitt i sin idrottssatsning. Vi pratar också om vad forskningen vet om ryggsmärta – varför den är så vanlig, varför smärta inte alltid betyder att något är skadat och varför rörelse och aktivitet ofta är en viktig del av vägen tillbaka.Medverkande: Eva Skillgate, professor i vårdvetenskap vid Sophiahemmet Högskola och professor i epidemiologi vid Karolinska Institutet, Soheila Zhaeentan, ortoped, Tommy Karls, Idrottspsykologisk rådgivare, före detta kanotist, nu på paralympics och Alma Larsson.Programledare: Ulrika Hjalmarson NeidemanProducent: Linnéa WanneforsReporter: Caroline Mathiasen och Mattias Lindgren

I tre dagar sitter Christian i ett fönsterlöst litet rum. Han ser ingenting och får treva sig fram till toaletten och äta utan att se maten. Lyssna på alla avsnitt i Sveriges Radios app. Han är mörkrädd men utmanar sig själv på ett så kallat dark retreat. Vad kommer hända? Hur ska det gå med Christians mörkrädsla? Veckans avsnitt omfamnar mörkret och undersöker vad det gör med oss människor att vistas i det.Medverkande: Caroline Erkers, psykolog, Rune Brautaset, professor i optometri vid Karolinska Institutet, Lars Westerlund från Föreningen Mörkret och Kylans glada vänner, Tone Elise Gjøtterud Henriksen överläkare vid akutavdelningen, Valen sjukhus i Norge, Christian Henriksson.Programledare: Ulrika Hjalmarson NeidemanProducent: Stina NäslundReporter: Mattias Lindgren

Idas storasyster blir svårt sjuk i anorexi i tonåren. Hon förändras snabbt och det påverkar hela familjen. Lyssna på alla avsnitt i Sveriges Radios app. Ida ser sin syster tyna bort. Hon vill förstå varför. Vad det här är för krafter som gör att det är möjligt att inte vilja äta? Idag forskar Ida Nilsson om vad det är som som styr hunger och mättnad i hjärnan. Anorexi är en svår sjukdom som kan bli livshotande. Veckans avsnitt undersöker vad man vet om de mekanismer som leder till att man blir sjuk i anorexia och vilka behandlingar som finns idag. Medverkande: Sanna Aila-Gustafsson, psykoterapeut och forskare vid Örebro Universitet, Emma Forsén Mantilla, psykolog och forskare vid Gymnastik- och idrottshögskolan, GIH, Anna Ehn, journalist och författare, Pouya Movahed, docent och överläkare inom psykiatri vid Lunds universitet, Ida Nilsson, docent o forskare i neurovetenskap Karolinska Institutet.Behöver du eller en närstående stöd? – Hit kan du vända dig:1177 1177 om anorexiaFrisk & Fri Riksföreningen mot ätstörningarTjejzonen Tjejzonens chat om ätstörningar för tjejer mellan 12-25Programledare: Ulrika Hjalmarson NeidemanProducent: Stina NäslundReporter: Olivia Sandell

Michelle Chew is a Professor of Anesthesiology and Intensive Care Medicine at Karolinska Institutet, Stockholm, Sweden, and editor for the British Journal of Anaesthesia. Hear her sharing her Perioperative Profile on TopMedTalk with Andy Cumpstey. After initial anaesthesia training in Denmark, she moved to Lund University, Sweden, combining clinical work and research, later establishing her own experimental haemodynamics group studying septic and haemorrhagic shock and myocardial changes. She balances academic and family life by prioritizing rather than seeking "life balance," noting challenges for women in academia despite Scandinavian support. She explains journal editing—from rapid assessment, literature checks, peer review coordination, to feedback synthesis—and entered the field via the European Journal of Anaesthesiology, later serving at BJA and other journals. She also describes developing clinical guidelines, emphasizing expert panels, systematic reviews, consensus, and local adaptation, with involvement in Scandinavian and European anesthesia societies. Throughout, she highlights lessons from mentors and family, especially her grandmother, stresses taking opportunities and putting in the work, and emphasizes that science and clinical medicine ultimately serve patients. -- Join us at Evidence Based Perioperative Medicine (EBPOM) World Congress 2026 in London. Be part of a global conversation as clinicians from around the world gather between 7-9th July at the British Library in London. Three days of evidence-based perioperative medicine, global insights, and expert debate—featuring speakers including Michael Marmot and Ken Rockwood. Register here - https://ebpom.org/product/ebpom-world-congress-2026/

Hur kan digitalt stöd främja hälsan hos små barn? Kjersti Graasvoll (vårdutvecklare) samtalar med Marie Löf (forskare och professor i nutrition) och Christine Delisle Nyström (forskare, biträdande lektor och docent i nutrition). Båda jobbar på Institutionen för medicin, Huddinge, Karolinska Institutet. Läs mer: Västra Götalandsregionen: Ministop - appen som hjälper din familj med bra mat- och rörelsevanor Capio: Ny app minskar stillasittande och stärker hälsan hos barn Karolinska Institutet: What´s the Ministop trial? (på engelska) Karolinska Institutet: Health4Life Karolinska Institutet: Marie Löf Karolinska Institutet: Christine Delisle Nyström Special Guests: Christine Delisle Nyström and Marie Löf .

A nossa convidada é a neurocientista Luísa Lopes. Licenciada em Bioquímica e doutorada em Neurociências, construiu um percurso científico que passou pela Universidade de Cambridge, no Reino Unido, pelo Karolinska Institutet, na Suécia, e pelo centro de investigação da Nestlé, na Suíça, antes de regressar a Portugal. Actualmente lidera um grupo de investigação no Instituto Gulbenkian de Medicina Molecular, onde estuda a neurobiologia do envelhecimento, isto é, as transformações do cérebro ao longo da vida. É autora do recente livro Programados para Amar (Contraponto), em que analisa o fenómeno do amor do ponto de vista da ciência. A conversa abordou o envelhecimento cerebral. O que significa, do ponto de vista da neurobiologia, envelhecer? Até que ponto o declínio cognitivo é inevitável — e o que sabemos hoje sobre a capacidade de um cérebro envelhecido para aprender, adaptar-se e preservar memórias? Que factores fazem a diferença entre envelhecer com resiliência cognitiva ou com perda acelerada de capacidades? Um outro tema foi o o do seu recente livro. O que acontece no cérebro quando nos apaixonamos, quando estamos a viver um amor duradouro ou quando temos uma experiência dolorosa de separação? Até onde vai a explicação biológica, isto é, onde estão os limites da ciência? Poderá o conhecimento neurocientífico ter implicações práticas na forma como vivemos as nossas relações? Ou, neste domínio, será melhor seguir os nossos instintos?See omnystudio.com/listener for privacy information.

The cinematographer Autumn Durald Arkapaw has been nominated for an Academy Award for “Sinners," an American horror film nominated this year for a record sixteen Oscars and thirteen BAFTAs. It's a period drama written and directed by Ryan Coogler, set in the 1930s South, with a supernatural twist. Autumn's previous credits include The Last Showgirl and Black Panther: Wakanda Forever. Anita talks to Autumn about her career so far and becoming the first woman of colour - and only the fourth woman ever - to be recognized in the Oscars cinematography category.Following the summer riots in 2024, the Women and Equalities Committee examined the impact of increasing tensions on women in Muslim communities across the UK and reported that the online, verbal and physical abuse and discrimination faced by Muslim women was having a ‘deeply damaging impact on individual lives and a corrosive effect on community cohesion'. Baroness Shaista Gohir OBE, CEO of the Muslim Women's Network and Iman Atta, CEO of Tell Mama join Anita to discuss the WEC's findings.AI companions are becoming increasingly common, with one in three adults now using them for conversation, advice and support. Now recent research from Bangor University has shown that many teen AI companion users believe their bots can think or understand. That research prompted Nicola Bryan, a reporter for BBC Wales News to investigate and acquire an "AI boyfriend" of her own in the process. Nicola talks to Anita about what happened next.Autism probably affects girls and boys equally, according to a long term study by the Karolinska Institutet in Sweden. The new research challenges previously held assumptions that autism is more common among males; it found that by the age of twenty, the male-to-female ratio of diagnoses was equal. But in children aged under ten, four boys are diagnosed for every one girl. To discuss the findings, Anita is joined by Doctor Judith Brown, Head of Evidence and Research at the National Autistic Society and Betsey, an autistic 18-year old university student.Presenter: Anita Rani Producer: Rebecca Myatt

Vad är det som avgör hur vår kropp åldras och hur kan vi bromsa förfallet? Sara Hägg, docent i molekylär epidemiologi på Karolinska Institutet, berättar om den senaste forskningen. Hosted on Acast. See acast.com/privacy for more information.

Covid-19 har på många sätt präglat våra liv under de senaste åren, och nya forskningsresultat fortsätter att ge oss insikt i hur immunförsvaret agerar i samband med viral infektion. Ett exempel på detta är den studie som Philip Curman, specialist i dermatologi vid Karolinska Universitetssjukhuset i Solna, disputerad inom genetiska hudsjukdomar och forskare inom dermatologisk epidemiologi vid Karolinska Institutet, nyligen publicerade i The Journal of Allergy and Clinical Immunology tillsammans med ett internationellt forskarlag.I studien, som baserades på den amerikanska elektroniska hälsodatabasen TriNetX, undersökte man sambandet mellan covid-19-infektion och typ 2-inflammatoriska sjukdomar, och fann en markant ökad risk för personer som haft covid-19 att utveckla astma, kronisk bihåleinflammation och/eller allergisk rinit. Däremot såg man ingen ökad risk för typ 2-inflammatoriska sjukdomar i huden, som atopisk dermatit, eller i matstrupen i form av eosinofil esofagit. En ännu tydligare skillnad framträdde vid jämförelse med individer som vaccinerats mot covid-19, vilket indikerar att vaccination inte bara skyddar mot infektion i sig, utan även verkar ha en viss förebyggande effekt mot vissa följdsjukdomar i luftvägarna. I detta avsnitt diskuterar han studiens upplägg och resultat, potentiella begränsningar och såväl planerade som pågående forskningsprojekt inom typ 2-inflammation, som förhoppningsvis kan bidra till ökad förståelse för immunaktivering och sjukdomsutveckling.Läs mer om den aktuella studien och pågående och kommande forskningsprojekt här:COVID-19 infection raises respiratory type 2 inflammatory disease risk, whereas vaccination is protective - ScienceDirectPhilip Curman | Karolinska Institutet

Welcome to Ozempic Weightloss Unlocked, the podcast that unpacks how this medication is reshaping health, lifestyle, and the future of weight management.Ozempic is a brand name for semaglutide, a medication originally approved to treat type two diabetes. It mimics a gut hormone that helps the pancreas release insulin, lowers blood sugar, slows stomach emptying, and signals the brain to feel full sooner. The result for many people is significant weight loss, which is why a higher dose of the same drug is sold separately for obesity under the name Wegovy, according to the United States Food and Drug Administration and the National Institutes of Health.Because of this dual effect on blood sugar and appetite, Ozempic has become a cultural phenomenon. Listeners hear about it from celebrities, social media, and even coworkers, but medical experts keep stressing one key point. These are prescription drugs meant for people with type two diabetes or with obesity and related health risks, not quick fixes for casual weight loss. Major medical groups such as the American Diabetes Association and the Obesity Society are pushing to protect access for patients who truly need them.Recently, attention has shifted to what happens beyond the number on the scale. Some people lose not only fat but also muscle, which can affect strength, mobility, and metabolism. Researchers at Karolinska Institutet and Stockholm University, writing in the journal Cell, report a new tablet treatment that increases fat burning and improves blood sugar while preserving muscle mass, and it works very differently from Ozempic. Instead of acting on appetite in the brain, it targets skeletal muscle directly, and early trials suggest it may be used alone or even combined with a drug like Ozempic in the future.At the same time, the competition in obesity medicine is heating up. Eli Lilly has developed a so called triple hormone drug called retatrutide that activates three receptors instead of one. Eli Lilly and coverage from outlets like ABC News report that in a large trial of people with obesity and knee osteoarthritis, participants on the highest dose lost nearly twenty nine percent of their body weight on average and saw a big drop in knee pain. While retatrutide is still in clinical trials and not yet approved, it shows how the field is racing to go beyond the results seen with Ozempic alone.For listeners, this rapid progress brings both excitement and responsibility. These medications can improve blood sugar, reduce cardiovascular risk, and help treat diseases linked to excess weight, but they can also cause nausea, vomiting, diarrhea, and in some cases gallbladder or pancreatic issues. Long term use may require monitoring of muscle mass, nutrition, and mental health. Physicians are now talking more about pairing these drugs with resistance training, adequate protein, and psychological support so that weight loss does not come at the cost of strength or well being.Ozempic has also raised bigger questions. Who should get access when supplies are limited. How will insurance handle long term therapy for what is often a chronic condition. And what happens if a person stops the medication and the hunger comes back. Early data suggest that for many, maintaining results may require ongoing treatment, much like blood pressure medicine.On Ozempic Weightloss Unlocked, we will keep tracking all of this. From new trials and pill based options, to combination therapies, insurance changes, and real world stories of how life looks on and off these medications, our goal is to give you clear, balanced information so you can have better conversations with your own health care team.Thank you for tuning in, and remember to subscribe so you never miss an update on the evolving world of Ozempic and weight loss science.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

Gaston är 14 och märker att han plötsligt är så morgontrött att han inte kan ta in vad någon säger. Under tonåren förskjuts dygnsrytmen. Lyssna på alla avsnitt i Sveriges Radios app. I tonåren blir det ofta svårt att komma upp på morgonen. Flera högstadieskolor testar just nu att senarelägga skolstarten. Eleverna får börja och sluta skoldagen en timme senare. - Många jublade när vi införde det. Jag är positiv, jag tror på det här, jag upplever att det blivit lugnare i klassrummet, säger högstadieläraren Júlía Sigurdardóttir.Veckans avsnitt handlar om dygnsrytm, sovmorgnar, tupplurar och om hur du kan göra för att återhämta dig från sömnbrist. Medverkande: John Axelsson, professor och sömnforskare vid Karolinska Institutet och Stocholms universitetLi Åslund, psykolog och forskare aktuell med boken “Tonårssömn”Malin Jakobsson, forskare som just nu studerar hur en timmes senare skolstart påverkar ungdomarna vid Hälsohögskolan, Jönköping. Júlía Sigurdardóttir, högstadielärareElin Kimland, utredare på LäkemedelsverketProgramledare: Ulrika Hjalmarson NeidemanProducent: Stina NäslundReporter: Olivia SandellBilden är en genrebild. Foto: Ulrika Hjalmarson Neideman.

Welcome to Ozempic Weightloss Unlocked, the show where we unpack how this powerful medication is reshaping medicine, health, and everyday life.Today we are diving into the very latest science on semaglutide, the drug sold as Ozempic for diabetes and Wegovy for obesity, and what new research means for listeners who are using it or thinking about it.A new real world study in the journal Current Medical Research and Opinion followed people on once weekly semaglutide for two full years. Researchers found that on average, patients lost about thirty nine pounds, or nearly seventeen percent of their body weight, and most kept that weight off over the full twenty four months. People also saw improvements in blood pressure, cholesterol, blood sugar, and many moved from prediabetes or diabetes back to normal blood sugar levels. That is important, because it confirms that Ozempic is not just a quick fix but can be part of long term weight management when it is continued and combined with lifestyle changes.At the same time, doctors are getting clearer about downsides. A recent analysis from researchers in Utah, reported by Ladbible, warned that Ozempic related weight loss can come with a drop in lean mass, including muscle, of around ten percent. That is less loss than some earlier crash diets have caused, but it still matters. Losing muscle can weaken strength, slow metabolism, and be especially risky for older adults. Experts now stress pairing Ozempic with enough protein, resistance exercise, and medical follow up to protect muscle.For older listeners, the Association of American Medical Colleges reports that trials suggest these drugs can be safe and effective after age sixty five, but that adults over seventy five were rarely studied. Clinicians are urging extra caution in seniors because they are more prone to side effects like nausea, dehydration, and muscle loss, and they may already be on multiple medications.Researchers are also uncovering surprising new uses. Memorial Sloan Kettering Cancer Center reports that glucagon like peptide drugs such as Ozempic may help people with obesity reduce their risk of several cancers linked to excess body fat, including breast and colon cancer. In an early study in breast cancer patients, these medications helped counteract the weight gain that often comes with treatment, which could improve long term heart and cancer outcomes if confirmed in larger trials.Scientists are even exploring effects on brain health. Imperial College London recently showed that another drug in the same family, called liraglutide, slowed brain shrinkage and cognitive decline in people with Alzheimer disease over one year. Patients on liraglutide had almost fifty percent less brain volume loss in key memory areas compared with placebo, and their thinking declined about eighteen percent more slowly. While this was not Ozempic itself, it suggests this whole class of drugs might play a future role in protecting the brain, and large phase three trials are now underway.There is also growing attention on mental health. Think Global Health highlights that when people lose even a modest amount of weight and improve metabolic health, their risk of depression and anxiety often falls. Some patients report better mood and fewer food cravings on Ozempic, while a small number describe emotional blunting or worries about identity after major weight loss. Regulators in Europe have examined rare reports of suicidal thoughts, but the United States Food and Drug Administration has said current evidence does not show a clear causal link. Still, it is essential for anyone on these medications to check in regularly with their care team about mood and mental health, not just the number on the scale.Finally, researchers are already working on what might come next. Scientists at Karolinska Institutet in Sweden recently reported a new experimental pill that burns fat by acting directly on muscle metabolism instead of appetite. In early human trials it improved blood sugar and body composition without reducing appetite or muscle mass. If it proves safe and effective, it may one day be used alone or together with drugs like Ozempic to achieve weight loss with fewer side effects.Taken together, the latest science tells us this. Ozempic and related medications can deliver major, sustained weight loss and improve heart and metabolic health. They may lower risks tied to obesity, from diabetes to some cancers, and could even have future roles in brain health. But they are not magic. Protecting muscle, supporting mental health, tailoring treatment to age, and combining medication with nutrition, movement, and sleep are all crucial.Thank you for tuning in to Ozempic Weightloss Unlocked. If you found this episode helpful, be sure to subscribe so you never miss the latest updates on Ozempic, weight loss, and health.This has been a quiet please production, for more check out quiet please dot ai. Some great Deals https://amzn.to/49SJ3QsFor more check out http://www.quietplease.aiThis content was created in partnership and with the help of Artificial Intelligence AI

I detta faktaspäckade avsnitt gästas vi av Erik Iwarsson, läkare inom klinisk genetik, för att reda ut begreppen kring ett ämne som blir alltmer aktuellt: genetisk testning. Vad är egentligen skillnaden på att testa embryon för ärftliga sjukdomar (PGT-M/SR) och att screena för kromosomavvikelser (PGT-A)? Vi dyker ner i varför PGT-A inte är tillåtet i Sverige idag och vad den nya SBU-rapporten säger om metodens effekt på "time to pregnancy". Erik förklarar även genetiken bakom upprepade missfall, hur NIPT-test fungerar och de etiska frågorna kring att screena donatorer. Ett otroligt lärorikt samtal som ger en djupare förståelse för både de medicinska möjligheterna och de svåra avvägningarna inom IVF-vården. Erik Iwarsson  är Docent i Medicinsk genetik vid Karolinska Institutet och överläkare vid Klinisk genetik, Karolinska Universitetssjukhuset. Avsnittet görs i samarbete med Merck. Ladda gärna ner deras patientbroschyrer via länken på Mercks Instagram "fertilitetsträdet" för mer kunskap.

Marta Paterlini"La pelle che pensa"Il tatto come linguaggio universale, tra filosofia, neuroscienze e tabù sociali.Codice Edizioniwww.codiceedizioni.itSottovalutato e dato per scontato, cos'è successo al tatto, l'atto più semplice e antico dell'umanità? Il tatto nasconde un mondo: è un linguaggio universale, un dialogo tra cervello e pelle, un atto di cura e una forma di resistenza in un'epoca in cui i corpi si allontanano. Centrale nei miti dell'Odissea e indagato dalla filosofia fin da Aristotele, il tatto è finalmente studiato dalle neuroscienze, che ne mostrano l'essenza: dalle carezze che alleviano il dolore nelle cure palliative alle fibre nervose che trasformano un massaggio in benessere; dalla fragilità di chi si chiude al contatto alla fame di pelle che genera disagio mentale. Nella società il tatto riflette visioni diverse del corpo, dell'identità e della cultura: la pelle sintetica della robotica, il tocco sociale, l'evoluzione dei saluti, le manipolazioni mediche, le politiche no-touch nelle scuole, fino alle ricerche sui canali Piezo del premio Nobel Ardem Patapoutian e alle fibre C-tattili del tocco affettivo. Sono questi i tasselli del mosaico che la neuroscienziata e divulgatrice Marta Paterlini ricompone in La pelle che pensa, mostrando come il tatto sia oggi sospeso tra tabù e necessità, paura del contatto e disperato bisogno di connessione. Perché toccare è curare, parlare, esistere.«In un mondo sempre più digitale, dove le relazioni spesso si sviluppano attraverso uno schermo, la pelle ci ricorda la magia del contatto diretto. Ogni abbraccio, ogni carezza, ogni stretta di mano è un ponte che ci avvicina, superando barriere culturali e linguistiche. Il tatto è uno dei primi canali attraverso cui esploriamo la realtà e instaura connessioni profonde tra gli individui. Ogni abbraccio sembra diverso perché tutti quelli che abbracciamo occupano spazio nel mondo in un modo diverso». Marta PaterliniMarta PaterliniNeurobiologa e giornalista scientifica freelance. Ha lavorato presso il Laboratory of Molecular Biology di Cambridge, in Inghilterra, e alla Rockefeller University di New York. Attualmente è senior scientist presso il Karolinska Institutet di Stoccolma, dove vive. Collabora con “Science”, “Nature” e “The Lancet”.Diventa un supporter di questo podcast: https://www.spreaker.com/podcast/il-posto-delle-parole--1487855/support.IL POSTO DELLE PAROLEascoltare fa pensarehttps://ilpostodelleparole.it/

The importance of odors to your taste buds might be greater than you think. Putu Agus Khorisantono, postdoctoral researcher at the Karolinska Institutet, delves into this. I am a cognitive and behavioural neuroscientist based in the Department of Clinical Neuroscience (Psychology Division) of Karolinska Institutet, with a background in statistics, functional neuroimaging and neuroeconomics. My […]

Det vanligaste försöksdjuren på Karolinska Institutet är möss, råttor och zebrafiskar, ibland förekommer också försök på primater. Hör forskarna förklara varför det ännu inte går att ersätta alla försöksdjur med alternativa metoder. Vi pratar om de tre R:en som står för reduce-refine-replace, och så blir det reportage från zebrafiskfaciliteten.

It's In the News.. a look at the top headlines and stories in the diabetes community. This week's top stories: It's World Diabetes Day and we have a LOT of news to get to! Daily oral insulin tested to prevent T1D, mothers and sons and a T1D link, stem cell updates, Tandem Android news, Omnipod's workplace campaign and more! Find out how to submit your Community Commercial Find out more about Moms' Night Out  Please visit our Sponsors & Partners - they help make the show possible! Learn more about Gvoke Glucagon Gvoke HypoPen® (glucagon injection): Glucagon Injection For Very Low Blood Sugar (gvokeglucagon.com) Omnipod - Simplify Life Learn about Dexcom   Check out VIVI Cap to protect your insulin from extreme temperatures The best way to keep up with Stacey and the show is by signing up for our weekly newsletter: Sign up for our newsletter here Here's where to find us: Facebook (Group) Facebook (Page) Instagram Twitter Check out Stacey's books! Learn more about everything at our home page www.diabetes-connections.com  Reach out with questions or comments: info@diabetes-connections.com Episode transcription with links:   Hello and welcome to Diabetes Connections In the News! I'm Stacey Simms and every other Friday I bring you a short episode with the top diabetes stories and headlines happening now. It's world diabetes day! It is marked every year on 14 November, the birthday of Sir Frederick Banting, who co-discovered insulin along with Charles Best in 1922.   WDD was created in 1991 by International Diabetes Federation (IDF) and the World Health Organization and became an official United Nations Day in 2006 with the passage of United Nations Resolution 61/225. There will be a ton of stuff in your feeds today and that's great! I'm going to keep this to a pretty normal in the news episode.. although I do have my own World Diabetes Day announcement – I want YOUR community commercials. You could have an ad for your event or your blog or your project right here! There's a post on the website explaining it all and I'll come back at the end of the episode and tell you more. XX The Primary Oral Insulin Trial (POInT) is the first large-scale clinical trial to test whether giving at-risk children daily oral insulin could prevent or delay type 1 diabetes (T1D). Conducted by researchers from Helmholtz Munich and the Technical University of Munich across five European countries, the study enrolled more than 1,000 children with a genetic risk for T1D. Results published in The Lancet show that while oral insulin did not prevent the development of islet autoantibodies—an early sign of diabetes—it was safe and well tolerated. Importantly, researchers found that some children who received oral insulin developed diabetes more slowly than those given a placebo, suggesting potential protective effects in certain genetic subgroups.   Further analysis revealed that the response to treatment depended on the child's insulin gene variant. Children with genetic versions that raise diabetes risk appeared to benefit, showing delayed onset of the disease, while those without the risk variant did not. These findings point toward a future of personalized prevention, where genetic screening could help identify which children might benefit most from oral insulin. Researchers will continue following the participants until age 12 to assess long-term effects. The study marks a major milestone in decades of diabetes prevention research, highlighting both the promise and complexity of developing tailored, early interventions against type 1 diabetes. XX Joint US-Chinese research looking at generating new beta cells from stomach cells. Upon turning on the "genetic switch," the human stomach cells were converted to insulin-secreting cells within the mice and resembled pancreatic beta cells with respect to gene and protein expression. Encouragingly, when those experiments were done with diabetic mice, insulin secreted from the transformed human cells helped control blood sugar levels and ameliorated diabetes. The scientists hope that a similar approach can be taken to convert cells from a patient's own stomach into insulin-secreting cells directly within the body. Importantly, additional studies are needed to address if this approach is safe and effective to be used in patients. https://www.technologynetworks.com/cell-science/news/human-stomach-cells-tweaked-to-make-insulin-406694 XX A new study in Nature Metabolism may help explain why children born to mothers with type 1 diabetes are less likely to develop the disease early in life compared to those whose fathers or siblings have it. Researchers looked at nearly 2,000 mothers and their children and found that  kids whose moms have type 1 diabetes show changes in their DNA that may actually help protect them. These aren't genetic mutations, but epigenetic changes — chemical tags that turn certain genes on or off. The study found these changes in genes tied to the immune system and type 1 diabetes risk, suggesting that a mother's condition during pregnancy can shape her child's immune response in a protective way. Scientists identified more than 500 areas of DNA where these changes occurred, many in regions that control how the body's immune system works. Most of the changes appeared to calm down the kind of overactive immune response that leads to type 1 diabetes. Researchers even created a "methylation score" to help measure this protective effect. They say the next step is to confirm these results in more diverse groups and figure out exactly how these DNA changes help prevent early diabetes. https://www.news-medical.net/news/20251110/Maternal-type-1-diabetes-may-protect-children-from-developing-the-disease.aspx XX A new study from Karolinska Institutet and Stockholm University reveals that sons born to mothers with type 1 diabetes may develop early vascular dysfunction—independently of metabolic health. The finding may help shape future strategies to prevent cardiovascular disease early in life.     Children of women with type 1 diabetes are known to be at increased risk of developing cardiovascular diseases. This new study, published in Cell Reports Medicine, is the first to show that the risk is linked to early dysfunction in blood vessel cells in sons, even before any metabolic issues arise. The team is now investigating the long-term effects of maternal diabetes, with a particular focus on why sons seem to be affected earlier than daughters. https://medicalxpress.com/news/2025-11-sons-mothers-diabetes-early-vascular.html XX A new study presented at Kidney Week 2025 has shown that the drug finn-uh-near-own  a nonsteroidal mineralocorticoid-receptor antagonist, significantly reduced albuminuria—a key marker of kidney damage—in people with type 1 diabetes (T1D) and chronic kidney disease (CKD). This is the first major breakthrough for this population in more than 30 years. Researchers found that patients taking finerenone saw a 25% average reduction in albuminuria compared to placebo, an improvement that suggests a lower long-term risk for dialysis or kidney transplant. The phase 3 FINE-ONE trial involved 242 adults with T1D and CKD, and results showed benefits as early as three months. The drug was generally well tolerated, with side effects similar to those seen in patients with type 2 diabetes, though mild hyperkalemia (high potassium levels) was slightly more common. Experts say the findings could change the way doctors treat kidney complications in type 1 diabetes, an area that hasn't seen new therapies since the early 1990s. Currently, treatment options rely on blood pressure and blood sugar management, along with renin-angiotensin system (RAS) inhibitors. Finerenone, which is already approved for type 2 diabetes-related CKD, targets overactivation of a receptor that drives kidney damage. Based on these results, Bayer plans to seek FDA approval in 2026 for use in people with T1D and CKD. Researchers and clinicians alike are calling the study "groundbreaking," noting that it opens the door to future research on how finerenone might not just slow kidney decline—but possibly prevent it altogether. https://www.medscape.com/viewarticle/finerenone-offers-hope-kidney-disease-type-1-diabetes-2025a1000uzi?form=login   XX This week, Tandem Diabetes Care (Nasdaq:TNDM) announced a major milestone for its Mobi miniature durable insulin pump system. San Diego-based Tandem revealed that it received FDA approval for the Android version of its Mobi mobile app. Clearance brings Mobi — which the company describes as the world's smallest, durable automated insulin delivery system — to more users. The pump, which pairs with Tandem's Control-IQ+ algorithm, previously worked with iOS software.   Tandem — one of the largest diabetes tech companies in the world — expects to begin a limited rollout next month, followed by full commercial availability in early 2026. This marks the latest milestone for the company, which continues to expand its offerings and widen its reach within the diabetes patient population.   We had a great interview with Tandem on our previous episode, but as I said at the time, it was coming before their earnings call. So here's an update: The company plans to submit the tubeless mobi to the fda before the end of this year.. possible approval and shipping date is hoped for by middle of 2026. Trials for their fully closed loop next-generation algorithm which we tlkaed abou ton the show should be launched in 2026 The Sigi patch pump will be developed and launched as a next-generation version of the Mobi Great job by Dr. David ? Ahn – he posted on IG after getting a message from tandem CEO John Sheridan? 1. First, the Tandem X3 *is* still absolutely in development, contrary to my speculation In yesterday's video. As many of you appropriately pointed out, there is definitely a market for a 300 unit pump, a pump with a screen, and a pump that does not require smartphone control. So from our brief chat, the sense I got that is that the X3 would be more of a refresh of the X2 with newer components, such as a USB-C connector and better memory, rather than a total redesign from the ground up. In terms of timing, all I could get was that it was "not too far distant in the future," which could mean anything I guess, but at least it's still on the way! 2. Next up, he also reassured me that they are working closely with Dexcom to support the G7 15 Day sensor within the next few months. I suspected as much, but it's always good to hear confirmation. 3. Lastly, he did confirm that Tandem is far along in developing a Caregiver/Follow app to allow the remote viewing of glucose and insulin data from a Tandem pump. He explained that it will be based on Sugarmate, the popular diabetes data dashboard app that Tandem acquired back in Jun 2020. While I don't know if every feature will make it into the Tandem caregiver app, Sugarmate is well-liked for its highly customizable dashboard and highly configurable alerts. Sugarmate even has the option to send a text message or phone call for urgent lows. Regardless, a true follow/Caregiver app will be welcomed with open arms by all caregivers and Tandem users who use Libre 3 Plus. https://time.com/7318020/worlds-top-healthtech-companies-2025/ XX Senseonics submits Eversense 365 – their year long implantable CGM for a CE mark, European Approval and expect to launch there soon. Eversense will be integrated with the sequel twist pump – again I'm hearing soon but no timeline. Intersting to note that one year inseration was approved in the US just about a year ago, so the first patients will be having their CGMs changed out – for the first time – pretty soon. https://www.drugdeliverybusiness.com/senseonics-q2-2025-sales-beat-ce-mark/ XX A confusing study out of Rutgers - these researcher say  metformin reduces some of the key benefits normally gained from regular physical activity. These include improvements in blood vessel health, physical fitness, and the body's ability to regulate blood sugar. Since 2006, doctors have typically encouraged patients with elevated blood sugar levels to combine metformin with exercise, expecting that the two proven treatments would produce stronger results together. However, the new research suggests this may not be the case. In this study, Exercise alone improved vascular insulin sensitivity, meaning blood vessels responded better to insulin and allowed more blood flow to muscles. This matters because insulin's ability to open blood vessels helps shuttle glucose out of the bloodstream and into tissues, lowering blood sugar after meals. But when metformin was added, the improvements shrank. The drug also diminished gains in aerobic fitness and reduced the positive effects on inflammation and fasting glucose. The findings don't mean people should stop taking metformin or exercising, Malin said. Instead, it raises urgent questions for doctors about how the two treatments can be combined and the need for close monitoring. Malin hopes future research will uncover strategies that preserve the benefits of both. https://scitechdaily.com/popular-diabetes-drug-metformin-may-cancel-out-exercise-benefits-study-warns/ XX XX https://www.medtechdive.com/news/Revvity-Sanofi-diabetes-test-Kihealth-seed-round/802133/   XX Dexcom recalled an Android app for its G6 glucose sensor due to a software problem that could cause the app to terminate unexpectedly. The issue could cause users to miss alarms, alerts or notifications related to estimated glucose values, according to a Food and Drug Administration database entry posted Oct. 30. The glucose sensor and the app are still available, but Dexcom required users to update the app to a new version. Dexcom began the recall on Aug. 28. The FDA designated the event as a Class 1 recall, the most serious kind. Dexcom sent a notification to customers in September about the software bug, which applies to version 1.15 of the G6 Android app. To use the app, customers must update it to a new version, according to the entry. https://www.medtechdive.com/news/dexcom-recall-g6-cgm-app/804630/ XX https://www.medscape.com/viewarticle/automated-insulin-delivery-boosts-glycemic-control-youth-2025a1000ub3 XX Tidepool partners with smart ring maker OURA.. press release says: to support a groundbreaking dataset intended to be broadly available for diabetes research, with participation limited to individuals who opt in through Tidepool.         Tidepool will pair biometric data from Oura Ring – sleep, activity, heart rate, temperature trends, and menstrual cycles – with diabetes device data, including continuous glucose monitors (CGMs) and insulin pumps. The result will provide researchers with an unprecedented dataset to accelerate the development of new clinical guidelines, next-generation diabetes technology, and personalized care models.   Recruitment is expected to launch in early 2026 through an IRB-approved study. By opting in to this study, participants consent to sharing their data with Tidepool's Big Data Donation Project, where data is de-identified and, with participant consent, shared with academics, researchers, and industry innovators to accelerate diabetes research. https://aijourn.com/tidepool-collaborates-with-oura-to-advance-inclusive-diabetes-research-through-wearables/ XX Eli Lilly launches two new clinical trials for baricitinib. These phase 3 trials will investigate whether the drug can delay T1D onset or progression and will open for recruitment soon. Baricitinib has the potential to extend the "honeymoon period" of T1D, meaning that it could preserve remaining insulin-producing beta cells earlier in disease progression. More beta cells mean better blood sugar management—and potentially reduced long-term complications. JAK inhibitors, including baricitinib, are already FDA-approved for other autoimmune diseases, such as rheumatoid arthritis, alopecia, and more. JAK signaling pathways are associated with overactive immune responses, so blocking this pathway may turn down the immune response. The phase 2 Breakthrough T1D-funded BANDIT study was key in showing that this drug is safe and effective in T1D. Importantly, baricitinib is a once-daily oral pill—meaning its use is simple and easy.   https://www.breakthrought1d.org/news-and-updates/two-new-trials-baricitinib-to-delay-t1d/ XX   Insulet is taking diabetes awareness into the workplace. Having found 79% of people with diabetes have faced bias or misunderstanding at work, the medtech giant is rolling out a range of resources intended to trigger changes in how workplaces approach the condition. Lots going on for Diabetes Awareness month.. some notables.. Insulet's "The Day Diabetes Showed up to Work" campaign. based on a survey of almost 10,000 people 79% of people with diabetes have faced bias or misunderstanding at work,.   Almost 90% of people with diabetes surveyed reported experiencing barriers at work due to their condition, and more than 40% of people with diabetes and caregivers said they have workplace-related anxiety tied to the metabolic disease. Around one-quarter of respondents reported fears that diabetes could limit opportunities or lead to workplace discrimination and judgment, and a similar proportion of people said they conceal their condition. https://www.fiercepharma.com/marketing/widespread-workplace-challenges-people-diabetes-spark-insulet-campaign XX New directive issued by the Trump administration could mean people seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity.   The guidance, issued in a cable the State Department sent to embassy and consular officials and examined by KFF Health News, directs visa officers to deem applicants ineligible to enter the U.S. for several new reasons, including age or the likelihood they might rely on public benefits.   The guidance says that such people could become a "public charge" — a potential drain on U.S. resources — because of their health issues or age.   The cable's language appears at odds with the Foreign Affairs Manual, the State Department's own handbook, which says that visa officers cannot reject an application based on "what if" scenarios, Wheeler said.   The guidance directs visa officers to develop "their own thoughts about what could lead to some sort of medical emergency or sort of medical costs in the future," he said. "That's troubling because they're not medically trained, they have no experience in this area, and they shouldn't be making projections based on their own personal knowledge or bias."   Immigrants already undergo a medical exam by a physician who's been approved by a U.S. embassy. https://www.npr.org/2025/11/12/nx-s1-5606348/immigrants-visas-health-conditions-trump-guidance XX SAN DIEGO---Nov. 14, 2025—DexCom, Inc. (NASDAQ: DXCM), the global leader in glucose biosensing, today unveiled 16 new diabetes advocates to represent people living with diabetes globally as part of Dexcom's World Diabetes Day campaign. The advocates – ranging from ages six to 68, spanning various types of diabetes, and hailing from four continents and five countries – were selected from 1,000 open call submissions based on their experiences advocating for people with diabetes in their communities. While each person's experience with diabetes is unique, they share a common passion for advocacy – and use of Dexcom's glucose biosensing technology. "Through advocacy, I strive to show others, especially children and newly diagnosed patients, that diabetes is not a limitation but an opportunity to grow stronger, inspire resilience and pursue ambitious goals," said Maria Alejandra Jove Valerio, one of Dexcom's new advocates. "What began as a diagnosis at age seven has grown into a lifelong mission to uplift others." This effort represents the first time Dexcom has sourced voices from the broader diabetes community specifically for its World Diabetes Day campaign, reinforcing Dexcom's history of and commitment to giving real people with diabetes a platform to share their story on a global stage. Through engaging, editorial-style portraits and deeply personal stories, the campaign highlights each advocate's personal experience with diabetes, what misconceptions about diabetes they'd like to dispel and how they want to inspire others with diabetes to discover what they're made of. To prepare for the spotlight, the group of advocates met in Los Angeles for a World Diabetes Day photoshoot which included a surprise visit from Grammy-nominated artist, actor, producer and Dexcom Warrior Lance Bass and author, producer, actress and Stelo*Ambassador Retta. This visit offered the advocates an opportunity to exchange stories and personal perspectives on the meaning of diabetes advocacy and how they live it each day. Behind the lens at the shoot was another member of the diabetes community—photographer Tommy Lundberg who lives with Type 1 diabetes. "Directing this photoshoot was nothing short of inspiring. Each of these advocates has a unique an XX On what would have been the 100th birthday of its visionary founder Alfred E. Mann, MannKind Corporation (Nasdaq: MNKD), in partnership with Alfred E. Mann Charities and The Diabetes Link, announced the launch of the Centennial Al Mann Scholarship. The new program will distribute $100,000 in scholarship funds to support at least 10 young adult students living with diabetes as they pursue higher education in life sciences.   Launched in Diabetes Awareness Month, the scholarship program honors Alfred E. Mann's enduring legacy of innovation, philanthropy, and his lifelong commitment to improving the quality of human life through medical advancement. Deeply passionate about giving back, Mr. Mann believed that his success should continue to serve humanity long after his passing, a belief that lives on through this initiative.   Each scholarship recipient will be awarded up to $10,000, distributed in annual installments of $2,500 throughout the course of their studies. Depending on the length of their degree program, recipients may receive between two and four installments (up to the full $10,000 per student). The first awards will be made for the 2026 academic year.   "Al Mann dedicated his life to helping people with serious medical conditions live longer, healthier lives. This scholarship is a reflection of that spirit," said Michael Castagna, PharmD, Chief Executive Officer of MannKind Corporation. "By supporting students living with diabetes who are pursuing careers in the life sciences and adjacent fields, we're honoring Al's legacy and investing in the future of innovation and care. This program is about giving back to the community we serve and empowering the next generation to carry forward Al's mission of making a meaningful difference in people's lives."   Alfred E. Mann Charities and MannKind will partner with The Diabetes Link to launch the program to serve young adults (aged 18-22) living with either type 1 or type 2 diabetes with their higher education goals. Those eligible will include incoming freshmen and current students pursuing 2- or 4-year degrees. The application window will open in early 2026, and for those interested in receiving notifications, an early interest form is available. More information about the scholarship will be shared on thediabeteslink.org.   "We're honored to partner with MannKind to expand access to higher education for young adults with diabetes," said Manuel Hernández, Chief Executive Officer of The Diabetes Link. "At a time when the cost of college continues to rise, this scholarship helps ease the financial burden and carries forward the spirit of Al Mann, whose vision and legacy continue to inspire us."   Mr. Mann was MannKind's Chairman of the Board from 2001 until his passing in February 2016 and served as Chief Executive Officer from November 2003 until January 2015. Driven by a desire to improve lives and fill unmet medical needs, for more than six decades he founded 17 companies and developed breakthrough medical devices, including insulin pumps, cochlear implants, cardiac pacemakers and retinal prostheses. In 1997, Mr. Mann saw the potential of a dry powder insulin formulation to change the way diabetes is treated and invested nearly $1 billion to help bring Afrezza® (insulin human) Inhalation Powder to market.   About MannKind MannKind Corporation (Nasdaq: MNKD) is a biopharmaceutical company dedicated to transforming chronic disease care through innovative, patient-centric solutions. Focused on cardiometabolic and orphan lung diseases, we develop and commercialize treatments that address serious unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.   With deep expertise in drug-device combinations, MannKind aims to deliver therapies designed to fit seamlessly into daily life.   Learn more at mannkindcorp.com.   About Alfred E. Mann Charities, Inc. Alfred E. Mann Charities, Inc. became active in 2016, following the passing of the organization's benefactor, Alfred E. Mann. Throughout his life, Al was passionate about philanthropy and was dedicated to prolonging and improving the quality of human lives through innovation in the fields of healthcare and the use of medical devices. It was important to Al that his success and assets continue to better human lives even after his own passing.   Alfred E. Mann Charities, Inc. (formerly known as Alfred E. Mann Family Foundation) has similarly placed its primary focus on healthcare and medical innovation, as our organization believes this is where we can have the greatest impact on humanity and human health throughout the world. Alfred E. Mann Charities, Inc. is also dedicated to promoting arts, culture, education, and community development across Los Angeles and throughout the world in order to best serve people and this planet.   Learn more at aemanncharities.org.   About The Diabetes Link The Diabetes Link is the only national nonprofit organization dedicated to empowering young adults living with diabetes. Founded by and for young adults, The Link serves this community through peer support, leadership opportunities, and practical, evidence-based resources designed for real life. Its network of campus and community chapters, active online community, and robust Resource Hub help young adults navigate the transitions of early adulthood while managing diabetes. The organization envisions a future where every young adult living with diabetes has

Sara Hägg, PhD is an associate professor at Karolinska Institutet, where she leads the Molecular Epidemiology of Aging Group. Her work focuses on human biomarkers of aging - especially biological age “clocks” built from epigenetic, proteomic, and metabolomic data - and on turning Nordic registry resources into clinically useful aging measures.In this episode:* What biological/epigenetic age clocks actually measure (and what they don't)* Accuracy, error bars, and why clocks aren't clinic-ready yet* Epigenetic vs. proteomic vs. metabolomic clocks - strengths and trade-offs* Organ-specific clocks (liver, ovary, kidney) and what they reveal* Why uncertainty spikes at life transitions; menopause as a natural “stress test”* PC (principal-component) clocks and noise reduction* Nordic registry & Swedish Twin Registry advantages; UK Biobank use* Direct-to-consumer tests: interpreting results and common pitfalls* AI's role in building/validating clocks and handling uncertainty* What would move the field fastest (data, standards, trials) and where Sweden standsShow notes for this episode will be available after this airs. Sign up for the LEVITY newsletter to get them straight to your inbox: reachlevity.comLEVITY is co-hosted by Patrick Linden, philosopher and author, and Peter Ottsjö, journalist and author.CHAPTERS00:00 Introduction03:27 Why Sweden lags behind in longevity science08:04 Nordic registry & Swedish twin registry advantages; UK Biobank use10:05 What is biological age?16:33 The rise of epigenetic clocks24:22 The importance of aging clocks32:04 Beyond methylation: proteomic and metabolomic clocks35:12 Organ clocks39:37 Do aging clocks generalize?54:37 The cost of aging clocks01:03:18 Uncertainty and AI01:17:10 Solving aging - where do we stand?01:28:10 Book recommendations Hosted on Acast. See acast.com/privacy for more information.

New research from the Karolinska Institutet in Sweden shows that your brain interprets certain aromas as taste, activating the same regions as sugar Retronasal smell — odor molecules rising from your mouth during eating — creates flavor, while orthonasal smell (sniffing) detects outside odors Functional MRI scans revealed that the insula, the brain's taste cortex, responds to sweet-associated aromas like vanilla or strawberry as if sugar were present Everyday experiences, such as food tasting bland during a cold, highlight the difference between taste vs. flavor and the role of retronasal airflow Sweet-linked aromas can help reduce added sugar in foods by enhancing perceived sweetness, though they do not change calorie or glucose content

Vad betyder det att Bari Weiss går till CBS? Och så tjafsar vi med Aftonbladet Plus om deras hårdvinklade nudeljournalistik. Lyssna på alla avsnitt i Sveriges Radio Play. Bakom kulisserna på bevakningen om hemkomna PalestinaaktivisterI början av veckan kom Greta Thunberg och flera andra aktivister slutligen hem till Sverige, efter en lång seglats mot Gaza och flera dagar i israeliskt fängelse. Redan på Arlanda var flera journalister på plats för att få svar på en central fråga: Hur illa behandlad blev Greta Thunberg i det israeliska ökenfängelset Ketziot? I ankomsthallen fick de inga svar utan hänvisades till en improviserad presskonferens på Sergels torg några timmar senare, omgivna av demonstranter. På plats var stämningen minst sagt märklig. Erik Petersson har träffat Ekots Mattias Pleijel och TV4:s Lisa Svensson.Varför rekryterar etablerade CBS News den etablissemangskritiska Bari Weiss?I veckan blev det klart att Bari Weiss, som för några år sedan lämnade sin roll som redaktör och opinionsjournalist på The New York Times med buller och bång, nu tar över som chefredaktör för en av USA:s största nyhetsredaktioner. Dessutom köper CBS moderbolag Paramount uppstickarsajten The Free Press som Weiss grundade i protest mot den wokekultur hon menade rådde i etablerade medier.Joanna Korbutiak ringde upp Expressens före detta chefredaktör Thomas Mattsson, numera bland annat senior advisor på Bonnier News, för en analys.Hårdvinklad nudeljournalistik”NY STUDIE: Risk att dö i förtid av populära rätten”, så löd rubriken till den låsta artikeln på Aftonbladets sajt, men stämmer det verkligen?Freddi Ramel fortsätter sitt korståg mot Aftonbladet Plus hälsojournalistik och intervjuar deras chef Helena Utter och Ingrid Larsson, näringsfysiolog på Karolinska Institutet.

In our first episode of the XXplored Women's Brain Health podcast, our resident expert and host Dr Laura Stankeviciute from University of Gothenburg engages with leading neuroscientists Professor Liisa Galea from University of Toronto and Dr Maria Teresa Ferretti from Karolinska Institutet to explore the critical intersection of sex, gender, and brain health. Together our guests discuss their personal journeys into neuroscience, the biological differences in brain health, the impact of hormonal changes, and the vulnerability of women to Alzheimer's disease. The conversation also addresses the barriers to inclusion in clinical research, the implications of neurosexism, and the importance of precision medicine. The episode emphasises the need for early diagnosis and the societal stigma surrounding women's health issues, while advocating for a more inclusive and evidence-based approach to brain health research and treatment. This first show sets the scene for what will be an ongoing series of shows, delivered within the Dementia Researcher podcast. Takeaways ● Sex differences shape the brain at every level – structure, hormones, immunity, and function. ● Menopause is a key vulnerability window for women's brain ageing and Alzheimer's risk. ● Women face higher Alzheimer's prevalence, not just because they live longer. ● Women were excluded from trials for decades, leaving dangerous gaps in knowledge. ● Fear of neurosexism and misunderstandings of feminism slowed progress. ● Precision medicine must include sex and gender or risk missing early diagnoses. ● Research funding and clinical guidelines lag far behind need. ● Momentum is building: younger researchers and public interest are pushing change. ● Core message: Different ≠ inferior. Diversity drives discovery. -- Find more information on our guests, and a full transcript of this podcast on our website at: https://www.dementiaresearcher.nihr.ac.uk/podcast -- The views and opinions expressed by guests in this podcast represent those of the guests and do not necessarily reflect those of University College London, Dementia Researcher or its funders. -- Follow us on social media: https://www.instagram.com/dementia_researcher/ https://www.facebook.com/Dementia.Researcher/ https://www.twitter.com/demrescommunity https://www.linkedin.com/company/dementia-researcher https://www.bsky.app/profile/dementiare…archer.bsky.social -- Download and Register with our Community App: https://www.onelink.to/dementiaresearcher

In this episode of the Me&My Health Up podcast, Anthony Hartcher interviews Cameron Borg, a leader in the nutrition space. Cameron shares his personal journey through various diets, including veganism, and how it led him to understand the importance of local and seasonal eating, outdoor living, and the impact of light exposure on health. They discuss practical tips for building healthy meals, the significance of meal timing, and the role of protein in nutrition. Cameron emphasises the importance of enjoying food and maintaining a healthy mindset around eating, while also providing insights on how to adapt to different environments and food availability.TakeawaysCameron's journey through veganism led to a deeper understanding of nutrition.Local and seasonal eating is crucial for health.Outdoor living and light exposure significantly impact well-being.Meal timing, especially breakfast, is important for health.Protein prioritisation is key in meal planning.Enjoying food with others enhances its benefits.Don't stress about occasional deviations in diet.The body has a remarkable ability to adapt to different diets.Nutrition is complex and not just about macros.A healthy mindset around food is essential for overall well-being.About Cameron Borg Cameron Borg is a nutritionist, podcaster, and science writer passionate about helping people rediscover balance and vitality. Through The Ricci Flow Nutrition Podcast and his Substack, he explores the intersection of science, philosophy, and health — from nutrition and light exposure to mindset and environment. Based in Sweden, Cameron continues his work as an educator and practitioner while studying at the Karolinska Institutet, sharing insights that empower others to reconnect with nature and the true foundations of wellbeing.  Connect with Cameron Borg: Substack: https://ricciflow.substack.com/ Website: https://www.ricciflownutrition.com/ YouTube: https://www.youtube.com/@RicciFlowNutrition Instagram: https://www.instagram.com/ricciflownutrition/ Twitter/X: https://x.com/ricciflowhealth LinkedIn: https://www.linkedin.com/in/cameron-borg/ Don't forget to like, comment, and follow for more health tips and wellness.   YouTube: / ⁠⁠⁠https://www.youtube.com/@memywellness⁠⁠⁠  Instagram:   / ⁠⁠⁠⁠https://www.instagram.com/meandmywellness/⁠⁠⁠⁠   Facebook:    / ⁠⁠⁠⁠https://www.facebook.com/meandmywellness.com.au⁠⁠⁠⁠      X (Twitter):   / ⁠⁠⁠⁠https://twitter.com/meandmywellness⁠⁠⁠⁠  LinkedIn:    / ⁠⁠⁠⁠https://www.linkedin.com/company/me&my-wellness/⁠⁠⁠⁠     About me&my health up & Anthony Hartcher:    me&my health up seeks to enhance and enlighten the well-being of others. Host Anthony Hartcher is the CEO of me&my wellness which provides holistic health solutions using food as medicine, combined with a holistic, balanced, lifestyle approach. Anthony holds three bachelor's degrees in Complementary Medicine; Nutrition and Dietetic Medicine; and Chemical Engineering.  Chapters00:00 Introduction to Nutrition Insights03:53 Cameron's Nutritional Journey06:35 The Importance of Local and Seasonal Eating08:52 Outdoor Living and Light Exposure11:28 Building Healthy Meals13:52 Meal Timing and Intermittent Fasting16:34 Understanding Macros and Protein Prioritization18:52 Mindset Around Food and Enjoyment21:32 Connecting with Cameron and Closing Thoughts

Erica får sin första tvångstanke när hon är 12 år gammal och hennes mamma drabbas av cancer. Tänk om jag vill att mamma dör, tänker Erica. Lyssna på alla avsnitt i Sveriges Radio Play. Tanken har ingen förankring i verkligheten men går inte att få bort. Tanken skapar mycket ångest och blir början på många år av jobbiga tankar. Till slut biktar hon sig och berättar det här för sin mamma. Veckans program tar itu med olika typer av jobbiga tankar som inte vill släppa taget. Det är katastroftankar, ältande, tvångstankar och tankar som ställer sig i vägen när du till exempel ska prestera något. Det finns sätt att stoppa tankar på, eller i varje fall få dem att blekna och ta mindre plats i ditt huvud. Medverkande: Linda Jüris, psykolog, Camilla Sköld, forskar och utbildar om Mindfullness vid Karolinska Institutet, Johan Plate, idrottspsykologisk rådgivare, Marie Banich, professor i kognitiv neurovetenskap på University of Colorado at Boulder.Programledare: Ulrika Hjalmarson NeidemanProducent: Stina NäslundReporter: Olivia Sandell

In this episode, Dr Tsen Vei Lim talks to Dr Danilo Romero, a licensed clinical psychologist at the Stockholm Centre for Dependency Disorders in Sweden. The interview covers his research report on the questionable generalisability of the Alcohol Use Disorders Identification Test – Consumption (AUDIT-C) when used as an outcome measure in clinical trials than as a primary care screening tool, highlighting the need for researchers and clinicians to reconsider their application of the AUDIT-C. · What is the AUDIT-C and why it is widely used in primary care and research? [01:13]· What made the authors question the generalisability of the AUDIT-C in clinical trials? [02:02]· The risks of using the AUDIT-C in clinical settings [03:03]· The reason for the ‘ceiling effect' of the AUDIT-C [04:21]· How the authors tested whether the AUDIT-C is useful in measuring treatment progress [05:15]· The key findings of the study [06:06]· What ‘collider bias' is and how it could manifest in studies that use the AUDIT-C [06:59]· What the findings mean for studies that have used AUDIT-C in the past [09:23]· How the findings contribute to policy or practice [10:30]· Whether the authors, as clinical psychologists, personally use the AUDIT-C [11:28]· Birds eye view of psychiatric screening measures [12:40]About Tsen Vei Lim: Tsen Vei is an academic fellow supported by the Society for the Study of Addiction, currently based at the Department of Psychiatry at the University of Cambridge. His research integrates computational modelling, experimental psychology, and neuroimaging to understand the neuropsychological basis of addictive behaviours. He holds a PhD in Psychiatry from the University of Cambridge (UK) and a BSc in Psychology from the University of Bath (UK). About Danilo Romero: Dr Romero, PhD, is a licensed clinical psychologist at the Stockholm Centre for Dependency Disorders in Sweden. He recently completed his doctorate at Karolinska Institutet, conducting a multimethod project to improve treatment engagement for substance use disorders after acute-care episodes. More broadly, his research covers digital psychiatry, mental health informatics, psychometrics, and novel psychological interventions for substance use disorders.The authors have no conflicts of interest to disclose. Original article: Questionable generalizability of Alcohol Use Disorders Identification Test-Consumption scoring warrants caution when used for outcome monitoring: Evidence from simulated and real-world trial data - https://doi.org/10.1111/add.70074The opinions expressed in this podcast reflect the views of the host and interviewees and do not necessarily represent the opinions or official positions of the SSA or Addiction journal.The SSA does not endorse or guarantee the accuracy of the information in external sources or links and accepts no responsibility or liability for any consequences arising from the use of such information. Hosted on Acast. See acast.com/privacy for more information.

This special episode was recorded at the mid-year symposium of the International Society of Pharmacovigilance (ISoP), 14–15 May 2025. Held in Uppsala, Sweden, the theme of the symposium was Improving information capture for safer use of medicines. The episode is an abridged recording of the concluding fireside chat, where Angela Caro Rojas (president of ISoP), Linda Härmark (director of the Drug Safety Research Unit in the UK), Ghita Benabdallah (national pharmacovigilance centre of Morocco, member of the IsoP advisory board), and Daniele Sartori (senior pharmacovigilance researcher at Uppsala Monitoring Centre), discuss patient engagement in pharmacovigilance.The symposium was a collaboration between ISoP and UMC. Want to know more?Visit the official website of the 2025 ISoP Mid-Year Symposium to learn more about its sessions, speakers and chairs. Not patient but im-patient – read about Sara Riggare's research on patient engagement and other topics.Listen to Henry Zakumumpa talk about his study on adverse event reporting quality in Uganda in this 2025 episode of Drug Safety Matters.Read about the PhD project of Tommy Emil Dzus, Improving causality assessment in pharmacovigilance for safe and sustainable use of medicines in health emergencies, at Oslo Metropolitan University, Norway.Sabine Koch is Head of the Department of Learning, Informatics, Management and Ethics (LIME), at Karolinska Institutet, Stockholm.Details on Mikael Hoffman's research can be found on his profile page on ResearchGate.Take a look at what's in store for participants at the 24th Annual Meeting of ISoP in Cairo, on October 24–27, 2025.Visit the websites of the Drug Safety Research Unit (DSRU), ISoP, Centre Anti Poison et Pharmacovigilance du Maroc, and Uppsala Monitoring Centre, to find out more about their work. Join the conversation on social mediaFollow us on Facebook, LinkedIn, X, or Bluesky and share your thoughts about the show with the hashtag #DrugSafetyMatters.Got a story to share?We're always looking for new content and interesting people to interview. If you have a great idea for a show, get in touch!About UMCRead more about Uppsala Monitoring Centre and how we work to advance medicines safety.

Dr. Cynthia Bulik is a clinical psychologist and one of the world's leading experts on eating disorders. She is the Founding Director of the University of North Carolina Center of Excellence for Eating Disorders and also the founder director of the Centre for Eating Disorders Innovation at Karolinska Institutet in Stockholm, Sweden. Dr. Bulik is Distinguished Professor of Eating Disorders in the Department of Psychiatry at UNC, Professor of Nutrition in the Gillings School of Global Public Health, and Professor of Medical Epidemiology and Biostatistics at Karolinska Institute.  Dr Bulik has received numerous awards for her pioneering work, including Lifetime Achievement Awards from the National Eating Disorders Association, the Academy for Eating Disorders, and the International Society of Psychiatric Genetics. She has written over 750 scientific papers, and several books aimed at educating the public about eating disorders.  Currently, Dr. Bulik's focus  is in the reconceptualization of eating disorders as being a metabo-psychiatric diseases. Food Junkies is keen to explore this interest in how metabolic disease plays a role in disordered eating: can this construct be the  common ground to start to understand the muddy waters  between eating disorders and food addiction?  In This Episode, You'll Learn:

Semaglutid har gjort sensation som medel mot övervikt. Nu hoppas forskare att det också ska kunna fungera mot allt från hjärtproblem till alzheimer. Lyssna på alla avsnitt i Sveriges Radio Play. Programmet sändes första gången 20240625.Hormonet semaglutid har startat en kapplöpning bland läkemedelsföretagen. Idag säljs det under flera olika varumärken som ett effektivt medel mot diabetes typ 2, och framför allt mot övervikt. Men nu upptäcker man att det har allt fler effekter. I studier ser man positiva resultat mot hjärt- och kärlsjukdomar och mot njurproblem.Det finns också förhoppningar om att semaglutid och närbesläktade substanser ska kunna fungera som ett slags bromsmedicin för patienter med Parkinsons och Alzheimers sjukdomar. Just nu pågår en internationell studie på alzheimerpatienter med deltagare på Karolinska Institutet i Huddinge. Men frågan är vad vi vet om de här relativt nya ämnenas biverkningar och långtidseffekter och inte minst vad de kommer att kosta sjukvården. Idag är det endast diabetiker, framför allt med typ 2, som får ämnet subventionerat. Är semaglutid och liknande hormoner på väg att bli vårt vanligaste läkemedel? Medverkande: Hindrik Mulder, professor i ämnesomsättning Lunds universitet; Kerstin Brismar, läkare och diabetesforskare Karolinska institutet Solna, Mikael Rydén; professor och diabetesforskare Karolinska institutet Huddinge; Jenny Vinglid, generalsekreterare Obesitas Sverige; Ylva Trolle Lagerros, docent och forskare Centrum för Obesitas Stockholm; Anne Börjesson Hanson, alzheimerforskare Karolinska institutet.Reporter: Tomas LindbladProducent: Björn Gunérbjorn.guner@sr.se

Sjukvården kan förbättras om man låter läkarna och patienterna hamna i centrum, med läkaretiken som central komponent. Idag är den rejält försvagad, om den inte rentav har avskaffats, skriver Johan Frostegård, professor i medicin vid Karolinska Institutet. Inläsare: Magnus Thorén

Aging is a complex process, but have you ever wondered how it differs between men and women? In this week's episode of the Everything Epigenetics podcast, Sara Hägg, an Associate Professor at Karolinska Institutet, and I discuss the fascinating differences in biological aging between sexes. We explore how genetics, hormones, and lifestyle choices contribute to aging disparities and what that means for longevity, disease risk, and overall health.You'll learn about: - How Sara Hägg became interested in aging research and what led her to study sex-specific differences - The major ways men and women age differently at the genetic, molecular, and epigenetic levels - The role of hormones like estrogen and testosterone in shaping the aging process - Why women typically live longer than men and what factors influence this disparity - How stress, diet, and environmental exposures impact aging uniquely for men and women - The latest epigenetic research uncovering biological sex differences in aging - How precision medicine may help tailor aging interventions based on sex-specific needs - Biomarkers of aging and how they reveal crucial insights into longevity and healthspanChapters:00:00 – Introduction to Everything Epigenetics Podcast02:00 – Meet Sara Hägg: Her Background and Research Focus06:30 – What Inspired Her to Study Aging and Sex Differences10:00 – How Do Men and Women Age Differently?15:30 – The Role of Hormones: Estrogen, Testosterone, and Aging20:00 – Why Do Women Live Longer Than Men?26:00 – Cellular and Epigenetic Differences in Male vs. Female Aging30:00 – The Impact of Stress, Diet, and Environment on Aging36:00 – Age-Related Diseases: Which Are More Common in Men vs. Women?40:00 – How Biomarkers Help Predict Aging and Disease Risk45:00 – The Future of Precision Medicine in Aging50:00 – Misconceptions About How Men and Women Age55:00 – Surprising Findings from Sara Hägg's Research58:00 – Closing Thoughts & How to Connect with Sara HäggSupport the showWhere to Find Us:Instagram Twitter Facebook Follow us on:Apple Podcast Spotify YouTube Visit our website for more information and resources: everythingepigenetics.com Thank you for joining us at the Everything Epigenetics Podcast and remember you have control over your Epigenetics, so tune in next time to learn more about how to harness this knowledge for your benefit.

Farewell to an Era: The Final Episode of the Papers PodcastDear Listeners, After more than a decade of insightful discussions, laughter, and learning, we are both excited and a bit teary-eyed to bring you the final episode of the Papers Podcast. This isn't just an episode; it's a heartfelt celebration of our journey together. From our humble beginnings recording in hotel rooms to becoming a beloved source of knowledge and camaraderie in the medical education community, we've cherished every moment with you.In this special farewell episode, join Jason, Jonathan, Lara, and Linda as they reflect on the incredible progress in our field, share personal anecdotes, and express their deepest gratitude to you, our loyal listeners. We've laughed, we've learned, and we've grown together, and now it's time to reminisce about the highlights and the friendships that have made this journey unforgettable. Whether you've been with us from the start or joined us along the way, this episode is a tribute to you. So, grab your favorite beverage, settle in, and let's take one last stroll down memory lane together. Thank you for being part of our story. We couldn't have done it without you.With heartfelt thanks and warmest regards,The Papers Podcast Team.Papers Podcast Episode website.PAPERs Podcast are:Hosts: Lara Varpio, Jason Frank, Jonathan Sherbino, Linda Snell.Technical Producer: Samuel Lundberg.Web Manager: Alex Alexandersson.Executive Producer: Teresa Sörö.This is a production from Karolinska Institutet.

Around the world, prison populations are bursting at the seams, but in some European countries, they are closing and reoffending rates are down. The trend has been attributed to a novel approach to justice, one that places the mental health of offenders at its heart. Forensic psychologist Dr Jenny Okolo investigates whether prison systems around the world could benefit from a similar approach. Jenny speaks to Dr Marrit de Vries from the Dutch Institute for Forensic Psychiatry and Psychology, to learn about a novel approach to mental health intervention pioneered in the Netherlands. And in Sweden, we hear from Dr Martin Lardén from Karolinska Institutet's Center for violence prevention, who discusses the efficacy of the Risk-Need-Responsivity model, an approach which positions the offender at the heart of the strategies devised to address the causes of their crime. And Rivelino Rigters, who draws on lived experience from within the criminal justice system, reflects on how a kinder, community-focused approach could stop crime from happening in the first place.